Market news — every asset we track

Assets

COYA

Exosomes Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 100+ Leading Players Wheeling the Therapeutics Landscape

13h agoBarchart.com

COYA

Coya Therapeutics stock maintained at Buy by H.C. Wainwright

Sep 25Investing.com

COYA

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

HOUSTON, September 08, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, "The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease," which highlights the expanding therapeutic app

Sep 8Yahoo! Finance Canada

COYA

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Medtronic Inc (MDT-N) from The Globe and Mail including charting and trades.

Aug 25The Globe and Mail

COYA

H.C. Wainwright reiterates Coya Therapeutics stock rating at buy

Aug 24Investing.com

COYA

Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI)

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

Jul 7The Globe and Mail

COYA

LXEO

PALI

This is the newest page. Registered accounts read further back.